Clinical trials of hydronidone, a modified pirfenidone derivative designed to more specifically target hepatic fibrosis via inhibition of TGF-β signaling, have shown significant benefit in Hepatitis B-driven liver fibrosis (101), suggesting that similar pharmacological approaches may improve liver fibrosis in the context of HIV. This evidence concerns the gene TGFB1 and Hepatic fibrosis.